These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33254278)

  • 1. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
    Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
    Oral Dis; 2022 Jan; 28(1):182-192. PubMed ID: 33254278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
    Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
    J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management.
    Tani M; Hatano K; Yoshimura A; Horibe Y; Liu Y; Sassi N; Oka T; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Nonomura N
    Sci Rep; 2024 Jun; 14(1):13451. PubMed ID: 38862617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
    Neal TW; Schlieve T
    J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
    Limones A; Sáez-Alcaide LM; Díaz-Parreño SA; Helm A; Bornstein MM; Molinero-Mourelle P
    Med Oral Patol Oral Cir Bucal; 2020 May; 25(3):e326-e336. PubMed ID: 32271321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw.
    Yasui T; Kimura M; Nagamine H; Yajima S; Karube T; Sato H; Asoda S; Hara S; Onizawa K
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Mar; 131(3):312-318. PubMed ID: 33431343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
    Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.
    Traboulsi-Garet B; Jorba-García A; Camps-Font O; Alves FA; Figueiredo R; Valmaseda-Castellón E
    Clin Oral Investig; 2022 Mar; 26(3):2371-2382. PubMed ID: 35124731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.